Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian anxiety CPG
Source-attributed clinical priorities
- Assess trauma symptoms, dissociation, depression, substance use, suicide risk and ongoing danger in a trauma-informed way.
- Offer an evidence-based trauma-focused psychotherapy as a core treatment when the person is ready and it is safe.
- Use medication for defined target symptoms or comorbidity, with measurement-based follow-up; avoid routine benzodiazepines.
- Confirm that symptoms persist beyond an acute stress response and cause meaningful distress or impairment.
sources for this section:Canadian anxiety CPG
Practical assessment and management workflow
1
Assess intrusion, avoidance, negative mood and cognition, hyperarousal, dissociation and functional impact.
2
Establish whether danger, abuse, displacement or occupational trauma is ongoing and address immediate safety.
3
Offer a structured trauma-focused therapy with pacing, consent and attention to culture and readiness.
4
Monitor nightmares, sleep, substance use, depression and suicide risk and measure functional recovery.
sources for this section:Canadian anxiety CPG
Safety, red flags and urgent escalation
- Imminent suicide risk, severe dissociation, psychosis or ongoing violence requires urgent safety intervention.
- Avoid routine benzodiazepines because dependence and interference with trauma therapy can outweigh benefit.
- Do not require detailed trauma retelling during an initial assessment when it is not clinically necessary.
sources for this section:Canadian anxiety CPG
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian anxiety CPG
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian anxiety CPG
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Anxiety Disorders Association of CanadaCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.